Functional Au nanoparticles for engineering and long-term CT imaging tracking of mesenchymal stem cells in idiopathic pulmonary fibrosis treatment

Bao, Hongli; Cheng, Shengnan; Li, Xiaodi; Li, Yuxuan; Yu, Chenggong; Huang, Jie; Zhang, Zhijun

doi:10.1016/j.biomaterials.2022.121731

Cited by 21 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before evaluating the in vivo effectiveness of ASNPs, an IPF mice model was established via intratracheal injection of BLM into C57BL/6 male mice, according to our previously reported protocol . By collecting lung tissues from the IPF mice at 7, 14, and 21 days postinjection of BLM, evident alveolar destruction and collagen accumulation were observed from hematoxylin–eosin (H&E) and Masson’s trichromatic staining images, indicating the successful construction of the IPF model (Figure S6).…”

Section: Resultsmentioning

confidence: 99%

Co-Delivery of Astaxanthin and siTGF-β1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy

Cao,

Yu,

Cheng

et al. 2024

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Alleviating the injury of type II alveolar epithelial cells (AEC 2s) and inhibiting the activation and differentiation of fibroblasts are significant for improving the therapeutic effect of idiopathic pulmonary fibrosis (IPF). To this aim, ionizable liposome nanoparticles (ASNPs) coloaded with antioxidant drug astaxanthin (AST) and small interfering RNA targeting transforming growth factor β1 (siTGF-β1) were developed for enhanced IPF therapy. ASNPs showed high loading and intracellular delivery efficiency for AST and siTGF-β1. After the injection of ASNPs in an IPF mice model, the loaded AST largely scavenged reactive oxygen species (ROS) in the diseased lung to reduce AEC2 apoptosis, thereby ensuring the integrity of the alveolar epithelium. Meanwhile, siTGF-β1, delivered by ASNPs, significantly silenced the expression of TGF-β1 in fibroblasts, inhibiting the differentiation of fibroblasts into myofibroblasts as well as reducing the excessive deposition of extracellular matrix (ECM). The combined use of the two drugs exhibited an excellent synergistic antifibrotic effect and was conducive to minimizing alveolar epithelial damage. This work provides a codelivery strategy of AST and siTGF-β1, which shows great promise for the treatment of IPF by simultaneously reducing alveolar epithelial damage and inhibiting fibroblast activation.

show abstract

Section: Resultsmentioning

confidence: 99%

Co-Delivery of Astaxanthin and siTGF-β1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy

Cao,

Yu,

Cheng

et al. 2024

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…MSCs modified with endogenous tissue transglutaminase have exhibited a dramatic increase in targeted efficiency to inflammatory endothelium compared with non-modified MSCs in both mice ear inflammation and acute/chronic liver injury models [ 132 ]. Researchers have employed a non-viral dual-functional nanocarrier fabricated by protamine sulfate stabilized Au nanoparticles for genetical engineering of MSCs and have also described a novel approach for enhanced therapeutic efficacy and long-term CT imaging tracking of transplanted MSCs [ 133 ].…”

Section: Strategies To Potentiate the Therapeutic Properties Of Mscs ...mentioning

confidence: 99%

Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications

Huai,

Zhu,

Zhang

et al. 2023

Cell Biosci

View full text Add to dashboard Cite

Liver disease is a leading cause of mortality and morbidity that is rising globally. Liver dysfunctions are classified into acute and chronic diseases. Various insults, including viral infections, alcohol or drug abuse, and metabolic overload, may cause chronic inflammation and fibrosis, leading to irreversible liver dysfunction. Up to now, liver transplantation could be the last resort for patients with end-stage liver disease. However, liver transplantation still faces unavoidable difficulties. Mesenchymal stromal/stem cells (MSCs) with their broad ranging anti-inflammatory and immunomodulatory properties can be effectively used for treating liver diseases but without the limitation that are associated with liver transplantation. In this review, we summarize and discuss recent advances in the characteristics of MSCs and the potential action mechanisms of MSCs-based cell therapies for liver diseases. We also draw attention to strategies to potentiate the therapeutic properties of MSCs through pre-treatments or gene modifications. Finally, we discuss progress toward clinical application of MSCs or their extracellular vesicles in liver diseases.

show abstract

“…Both are considered to be of low cytotoxicity. While Au can enhance CT-imaging ( Bao et al, 2022 ) and ultrasound imaging ( Li et al, 2018 ), iron(II,III) oxide, or magnetite, nanoparticles had been widely used for MR contrasting ( Olariu et al, 2011 ; Yiu et al, 2012 ; Yue et al, 2022 ) due to their superparamagnetic property. In addition, magnetic iron oxide nanoparticles (including maghemite, γ -Fe 2 O 3 ) have also been tested for targeted drug delivery ( Kim et al, 2020 ) and hyperthermia ( Wang et al, 2022 ), using an external magnetic field.…”

Section: Gold-iron Oxide (Au/fe 3 O 4 ...mentioning

confidence: 99%

Gold-iron oxide (Au/Fe3O4) magnetic nanoparticles as the nanoplatform for binding of bioactive molecules through self-assembly

Lau

Åhlén²,

Cheung³

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Nanomedicine plays a crucial role in the development of next-generation therapies. The use of nanoparticles as drug delivery platforms has become a major area of research in nanotechnology. To be effective, these nanoparticles must interact with desired drug molecules and release them at targeted sites. The design of these “nanoplatforms” typically includes a functional core, an organic coating with functional groups for drug binding, and the drugs or bioactive molecules themselves. However, by exploiting the coordination chemistry between organic molecules and transition metal centers, the self-assembly of drugs onto the nanoplatform surfaces can bypass the need for an organic coating, simplifying the materials synthesis process. In this perspective, we use gold-iron oxide nanoplatforms as examples and outline the prospects and challenges of using self-assembly to prepare drug-nanoparticle constructs. Through a case study on the binding of insulin on Au-dotted Fe3O4 nanoparticles, we demonstrate how a self-assembly system can be developed. This method can also be adapted to other combinations of transition metals, with the potential for scaling up. Furthermore, the self-assembly method can also be considered as a greener alternative to traditional methods, reducing the use of chemicals and solvents. In light of the current climate of environmental awareness, this shift towards sustainability in the pharmaceutical industry would be welcomed.

show abstract

Functional Au nanoparticles for engineering and long-term CT imaging tracking of mesenchymal stem cells in idiopathic pulmonary fibrosis treatment

Cited by 21 publications

References 53 publications

Co-Delivery of Astaxanthin and siTGF-β1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy

Co-Delivery of Astaxanthin and siTGF-β1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy

Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications

Gold-iron oxide (Au/Fe3O4) magnetic nanoparticles as the nanoplatform for binding of bioactive molecules through self-assembly

Contact Info

Product

Resources

About